The Concept of CMR
Slides, videos and moreManaging CMR
Preventing Type 2 Diabetes
Targeting Abdominal Obesity
- 1Key Points (1 page)
- 2Targeting Abdominal Obesity to Manage the Metabolic Syndrome (1 page)
- 3Lifestyle Interventions (5 pages)
- 4Pharmacotherapy for the Prevention of Type 2 Diabetes (4 pages)
- 5References (1 page)
Pharmacotherapy for the Prevention of Type 2 Diabetes
11 of 12
In summary, pharmacological compounds designed to mobilize atherogenic intra-abdominal fat need to be developed in order to improve the diabetic dyslipidemia and disruption of plasma glucose-insulin homeostasis caused by excess intra-abdominal fat.
Given that abdominal obesity is one of the most prevalent forms of type 2 diabetes, therapeutic approaches should focus on reducing intra-abdominal adipose tissue. This should have an impact on the causal pathways leading to insulin resistance, impaired glucose tolerance, and type 2 diabetes. Very few pharmacological compounds target intra-abdominal adipose tissue directly. Health professionals should focus first on reshaping patient lifestyles through increased physical activity and better eating habits. These measures have proven effective in reducing intra-abdominal fat and should be promoted to the general population as valid ways to prevent obesity-related health problems.
11 of 12
